In 2022, is financing in the domestic medical and health sector still "hot"? According to incomplete statistics in the industry, in the past week (from August 1, 2022 to August 7, 2022), a total of 42 investment and financing events in the domestic medical and health field occurred.
Over US$100 million, for example, Taibang Bio received US$300 million in strategic financing, and Viterilon received US$200 million in Series B financing
.
From the perspective of the sub-sectors with a large number of financing projects, there are 16 in the fields of medicine, medical equipment and hardware, and 5 in the field of biotechnology
.
Is financing in the domestic medical and health sector still "hot"? Emerging tracks have attracted a lot of attention (Image source: Pharmaceutical Network)
In fact, from the perspective of the overall environment, the trend of investment and financing in the domestic medical and health field is slowing down in 2022.
In the first half of the year, there were 632 investment and financing events in the national medical and health field, and the disclosed investment and financing amount was 115.
2 billion yuan, which is the same as the above Compared with the 578 investment and financing events in the same period last year, the increase in number is not obvious
.
In the first half of the year, most of the investment and financing projects in the medical and health field still focused on innovative drugs, medical devices, and corporate services such as CRO and CDMO.
The number of investment and financing events reached 161, 150, and 105 respectively.
.
It is worth mentioning that in the first half of this year, investors are enthusiastic about emerging pharmaceutical tracks, such as stem cell therapy, immune cell therapy, and gene therapy
.
Among them, there were 16 financing events in the field of stem cell therapy, and 7 financing events exceeded 100 million yuan; 18 financing events occurred in the field of immune cell therapy, and 7 financing events exceeded 100 million yuan; there were more financing events in the field of gene therapy.
There are 26 cases in total, and 10 cases exceed 100 million yuan
.
Industry analysts pointed out that behind the frequent investment and financing of these emerging tracks, the market prospects of these industries are widely optimistic by investors
.
Stem cell therapy, also known as regenerative medicine technology, has high hopes in repairing the body's own tissues and is one of the current research hotspots in the medical and health field
.
In recent years, the rapid development of stem cell therapy in China, and continuous breakthroughs under the continuous advancement of technology, has accelerated the pace of clinical application in many fields such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, cardiovascular and cerebrovascular diseases, and has broad market prospects.
.
Data show that the size of China's stem cell medical market has exceeded 70 billion yuan in 2019, and it is expected that by 2024, the market size of this industry will exceed 130 billion yuan
.
If stem cells are added, then immune cells are subtracted, which means that the collected autologous immune cells are cultured in vitro to expand their number and function, and then return to the human body to activate and enhance the body's immunity.
ability
.
This approach holds great promise in the treatment of cancer and other diseases
.
Among them, CAR-T cell therapy, as a new type of cellular immunotherapy, has become more expensive in clinical applications in recent years.
Since the price of its imported products is as high as one million, domestic pharmaceutical companies are actively deploying.
Among them, Fosun Kite's CAR-T cell therapy The therapeutic product "Yikaida" has been launched in China, and similar products such as WuXi Junuo and Legend Bio have also been launched one after another.
In addition, many pharmaceutical companies have developed new products
.
In the domestic market space, with the increase in the number of cancer patients in China, the industry expects that the CAR-T market will continue to expand, growing to 5.
3 billion yuan by 2024, and further growing to 28.
9 billion yuan in 2030
.
Gene therapy is a technology that modifies human genes to treat or cure diseases.
It also has potential in the treatment of cancer, genetic diseases, infectious diseases and other diseases, and has become one of the fields of concern in the pharmaceutical industry
.
So far, more than 20 gene therapies have been launched worldwide
.
In China, domestic pharmaceutical companies are also actively deploying this track in recent years, such as Kanghong Pharmaceutical, Suoyuan Bio, and Refine Bio
.
According to industry forecasts, with the further improvement of the global medical and biological level, the market size of the global gene therapy industry will grow to US$4.
3 billion in the future
.
